Deutsche Bank
ORIC icon

Deutsche Bank’s Oric Pharmaceuticals ORIC Stock Holding History

Deutsche Bank’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$650K Buy
51,333
+6,396
+14% +$72.6K ﹤0.01% 2439
2025
Q4 		$368K Buy
44,937
+2,440
+6% +$28.1K ﹤0.01% 2720
2025
Q3 		$510K Buy
42,497
+3,920
+10% +$41.2K ﹤0.01% 2527
2025
Q2 		$392K Sell
38,577
-13,399
-26% -$90K ﹤0.01% 2578
2025
Q1 		$290K Sell
51,976
-5,461
-10% -$47.8K ﹤0.01% 2770
2024
Q4 		$464K Buy
57,437
+18,745
+48% +$172K ﹤0.01% 2647
2024
Q3 		$397K Buy
38,692
+9,331
+32% +$92.3K ﹤0.01% 2593
2024
Q2 		$208K Buy
29,361
+4,036
+16% +$36.1K ﹤0.01% 2780
2024
Q1 		$348K Buy
25,325
+549
+2% +$6.52K ﹤0.01% 2520
2023
Q4 		$228K Sell
24,776
-967
-4% -$6.99K ﹤0.01% 2793
2023
Q3 		$156K Buy
25,743
+3,808
+17% +$31.2K ﹤0.01% 2931
2023
Q2 		$170K Sell
21,935
-3,232
-13% -$18.4K ﹤0.01% 2983
2023
Q1 		$143K Hold
25,167
– – ﹤0.01% 3172
2022
Q4 		$148K Hold
25,167
– – ﹤0.01% 3123
2022
Q3 		$81K Sell
25,167
-10,103
-29% -$40.4K ﹤0.01% 3429
2022
Q2 		$158K Buy
35,270
+17,886
+103% +$71.4K ﹤0.01% 3298
2022
Q1 		$93K Sell
17,384
-2,038
-10% -$18.4K ﹤0.01% 3608
2021
Q4 		$285K Sell
19,422
-2,482
-11% -$38.7K ﹤0.01% 3180
2021
Q3 		$458K Buy
21,904
+1,692
+8% +$34.3K ﹤0.01% 3096
2021
Q2 		$358K Buy
20,212
+3,529
+21% +$77.3K ﹤0.01% 3446
2021
Q1 		$408K Buy
16,683
+137
+0.8% +$4.33K ﹤0.01% 3232
2020
Q4 		$560K Buy
16,546
+11,679
+240% +$335K ﹤0.01% 2831
2020
Q3 		$122K Buy
4,867
+422
+9% +$10K ﹤0.01% 3456
2020
Q2 		$150K Buy
+4,445
New +$142K ﹤0.01% 3264

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Deutsche Bank's ORIC Position: Q1 2026 in Review

Deutsche Bank increased its Oric Pharmaceuticals (ORIC) stake by 14% in Q1 2026, buying an estimated $72.6K and bringing the position to 51,333 shares worth $650K. The position accounts for ﹤0.01% of the portfolio, ranked #2439.

Deutsche Bank first reported a position in ORIC in Q2 2020 and has held it in 24 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Deutsche Bank held 51,333 shares of Oric Pharmaceuticals worth $650K as of Q1 2026.
  • Deutsche Bank bought 6,396 Oric Pharmaceuticals shares in Q1 2026, an estimated $72.6K.
  • Oric Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #2439 holding.
  • Deutsche Bank first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.